A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.
Clinical trial NCT01346540 · COMPLETED
Trial details
- NCT number
- NCT01346540
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2011-04-14
- Primary completion
- 2013-04-25
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.